New insulin pump aims to keep blood sugar in check with fewer mealtime shots

NCT ID NCT06865989

Completed Disease control Sponsor: Insulet Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared a new version of the Omnipod insulin pump (SmartAdjust 2.0) to the current Omnipod 5 in 132 people with type 1 or type 2 diabetes, ages 2 to 70. Participants used each system for about a month to see if the new one is safe and helps keep blood sugar in a healthy range. The goal was to improve glucose control while reducing the number of insulin shots needed at meals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 1 diabetes mellitus 2 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1, TYPE 2

Contacts and locations

Show contact details

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Diabetes and Glandular Disease Clinic

San Antonio, Texas, 78229, United States
Henry Ford

Detroit, Michigan, 48202, United States
International Diabetes Center

Minneapolis, Minnesota, 55416, United States
Joslin Diabetes Center

Boston, Massachusetts, 02215, United States
Northwestern University

Chicago, Illinois, 60611, United States
Sansum Diabetes Research Institute

Santa Barbara, California, 93105, United States
University Hospitals Cleveland

Cleveland, Ohio, 44106, United States
University of Colorado Denver

Aurora, Colorado, 80045, United States
University of Southern California

Los Angeles, California, 90022, United States
Yale University School of Medicine

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.